Advertisement
Journal Home
Search for

Volume 36, Issue 1, Pages 17-27 (January 2008)


View previous. 4 of 12 View next.

Hypoxia alters progression of the erythroid program

Heather M. Rogersa, Xiaobing Yub, Jie Wenc, Reginald Smitha, Eitan Fibachd, Constance Tom NoguchiaCorresponding Author Informationemail address

Received 20 February 2007; received in revised form 24 July 2007; accepted 8 August 2007. published online 16 October 2007.

Hypoxia can induce erythropoiesis through regulated increase of erythropoietin (Epo) production. We investigated the direct influence of oxygen tension (pO2) in the physiologic range (2–8%) on erythroid progenitor cell differentiation using cultures of adult human hematopoietic progenitor cells exposed to decreasing (20% to 2%) pO2 and independent of variation in Epo levels. Decreases in hemoglobin (Hb)-containing cells were observed at the end of the culture period with decreasing pO2. This is due, in part, to a reduction in cell growth and, at 2% O2, a marked increase in cell toxicity. Analysis of the kinetics of cell differentiation showed an increase in the proportion of cells with glycophorin-A expression and Hb accumulation at physiologic pO2. Cells were characterized by an early induction of γ-globin expression and a delay and reduction in peak levels of β-globin expression. Overall, fetal Hb and γ-globin expression were increased at physiologic pO2, but these increases were reduced at 2% O2 as cultures become cytotoxic. At reduced pO2, induction of Epo-receptor (Epo-R) by Epo was decreased and delayed, analogous to the delay in β-globin induction. The oxygen-dependent reduction of Epo-R can account for the associated cytotoxicity at 2% O2. Epo induction of erythroid transcription factors, EKLF, GATA-1, and SCL/Tal-1, was also delayed and decreased at reduced pO2, consistent with lower levels of Epo-R and resultant Epo signaling. These changes in Epo-R and globin gene expression raise the possibility that the early increase of γ-globin is a consequence of reduced Epo signaling and a delay in induction of erythroid transcription factors.

a Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Md., USA

b Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Md., USA

c Oral Immunity and Infection Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Md., USA

d Department of Hematology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

Corresponding Author InformationOffprint requests to: Constance Tom Noguchi, M.D., Molecular Medicine Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, MSC 1822, Building 10, Room 9N307, Bethesda, MD 20892-1822

PII: S0301-472X(07)00522-X

doi:10.1016/j.exphem.2007.08.014


View previous. 4 of 12 View next.